Status | Study |
NOT_YET_RECRUITING |
Study Name: Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma Condition: Date: 2023-06-01 Interventions: 10mg/kg administered intravenously (IV) |
RECRUITING |
Study Name: Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis Condition: Date: 2023-05-23 Interventions: Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the n |
RECRUITING |
Study Name: Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma Condition: Nasopharyngeal Carcinoma Date: 2020-01-06 Interventions: Camrelizumab 200mg every 21 days (3 weeks) for up to 18 cycles, from 4 to 12 weeks after the completion of radiotherapy. |
RECRUITING |
Study Name: Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma Condition: Nasopharyngeal Carcinoma Date: 2019-01-26 Interventions: nimotuzumab 200mg/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT |
Recruiting |
Study Name: Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma Condition: Nasopharyngeal Carcinoma Date: 2017-04-21 Interventions: Drug: Apatinib mesylate tablet Patients with locally recur |
Recruiting |
Study Name: Effect of the Plasma EBV DNA Change During Chemoradiotherapy in Nasopharyngeal Carcinoma Condition: Nasopharyngeal Carcinoma Date: 2017-03-06 Interventions: Diagnostic Test: Plasma EBV DNA Parameters analyzed will include (1) the change pattern of plasma EBV DN |
Not yet recruiting |
Study Name: IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma Condition: Nasopharyngeal Carcinoma Date: 2017-02-15 Interventions: Radiation: Intensity modulated radiotherapy |
Recruiting |
Study Name: Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Condition: Nasopharyngeal Carcinoma Date: 2016-10-26 Interventions: Drug: Capecitabine Patients will receive capecitabine (650 mg/m2 bid, p.o.,d1-21,q3wks; co |
Recruiting |
Study Name: TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma Condition: Nasopharyngeal Carcinoma Date: 2016-09-21 Interventions: Other: Drug: Taxol,cisplatin and capecitabine |
Not yet recruiting |
Study Name: Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma Condition: Nasopharyngeal Carcinoma Date: 2016-09-13 Interventions: Drug: Endostar intravenous inf |